Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.

Objective: To evaluate short-term safety and steady-state systemic pharmacokinetics (PK) of latanoprost acid in pediatric subjects with glaucoma or ocular hypertension who received the adult latanoprost dose.

Design: Phase 1, open-label, multicenter study.

Participants: Pediatric patients of 3 age groups (<3, 3-<12, and 12-<18 years) and adults (≥18 years) receiving latanoprost ophthalmic solution 0.

Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.

Objective: To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma.

Design: Prospective, randomized, double-masked, 12-week, multicenter study.

Participants: Individuals aged ≤18 years with glaucoma.